Characterization of the humoral and cellular immunity induced by a recombinant BCG vaccine for the respiratory syncytial virus in healthy adults

Simple item page
dc.contributor.authorPacheco, Gaspar A.
dc.contributor.authorAndrade, Catalina A.
dc.contributor.authorGalvez, Nicolas M. S.
dc.contributor.authorVazquez, Yaneisi
dc.contributor.authorRodriguez-Guilarte, Linmar
dc.contributor.authorAbarca, Katia
dc.contributor.authorGonzalez, Pablo A.
dc.contributor.authorBueno, Susan M.
dc.contributor.authorKalergis, Alexis M.
dc.date.accessioned2025-01-20T20:08:31Z
dc.date.available2025-01-20T20:08:31Z
dc.date.issued2023
dc.description.abstractIntroductionThe human respiratory syncytial virus (hRSV) is responsible for most respiratory tract infections in infants. Even though currently there are no approved hRSV vaccines for newborns or infants, several candidates are being developed. rBCG-N-hRSV is a vaccine candidate previously shown to be safe in a phase I clinical trial in adults (clinicaltrials.gov identifier #NCT03213405). Here, secondary immunogenicity analyses were performed on these samples. MethodsPBMCs isolated from immunized volunteers were stimulated with hRSV or mycobacterial antigens to evaluate cytokines and cytotoxic T cell-derived molecules and the expansion of memory T cell subsets. Complement C1q binding and IgG subclass composition of serum antibodies were assessed. ResultsCompared to levels detected prior to vaccination, perforin-, granzyme B-, and IFN-& gamma;-producing PBMCs responding to stimulus increased after immunization, along with their effector memory response. N-hRSV- and mycobacterial-specific antibodies from rBCG-N-hRSV-immunized subjects bound C1q. ConclusionImmunization with rBCG-N-hRSV induces cellular and humoral immune responses, supporting that rBCG-N-hRSV is immunogenic and safe in healthy individuals.
dc.fuente.origenWOS
dc.identifier.doi10.3389/fimmu.2023.1215893
dc.identifier.issn1664-3224
dc.identifier.urihttps://doi.org/10.3389/fimmu.2023.1215893
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/91911
dc.identifier.wosidWOS:001037832100001
dc.language.isoen
dc.revistaFrontiers in immunology
dc.rightsacceso restringido
dc.subjecthRSV
dc.subjectvaccine
dc.subjectBCG
dc.subjectclinical trial
dc.subjectcellular response
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleCharacterization of the humoral and cellular immunity induced by a recombinant BCG vaccine for the respiratory syncytial virus in healthy adults
dc.typeartículo
dc.volumen14
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas